Wockhardt has received final approval from the US FDA for marketing 5mg/5ml of oxycodone HCI liquid. The company is launching the product soon and will be amongst the few generic versions of this product in the market.
Oxycodone is used extensively in management of pain, especially in opioid tolerant patients. Wockhardt already markets several other controlled substance products in the US and generally has a leading presence in the liquid formulations segment. In the US generic pharma market, Wockhardt has been consistently growing market shares for all its products.